These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37744290)

  • 21. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach.
    Hyman DW; Almerey T; Mujkanovic A; Hammons I; Tice M; Stauffer JA
    Am Surg; 2022 Aug; 88(8):1868-1874. PubMed ID: 35465681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach?
    Puleo A; Malla M; Boone BA
    Pancreas; 2022 Oct; 51(9):1083-1091. PubMed ID: 37078929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
    Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
    J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.
    Nakajima K; Ino Y; Naito C; Nara S; Shimasaki M; Ishimoto U; Iwasaki T; Doi N; Esaki M; Kishi Y; Shimada K; Hiraoka N
    Br J Cancer; 2022 Mar; 126(4):628-639. PubMed ID: 34824448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic Cancer: A Review.
    Park W; Chawla A; O'Reilly EM
    JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factors-Literature Review.
    Gulla A; Hashimoto D; Wagner D; Damaseviciute R; Strupas K; Satoi S
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744019
    [No Abstract]   [Full Text] [Related]  

  • 33. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
    Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
    HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
    Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
    Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
    Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
    JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
    Blair AB; Yin LD; Pu N; Yu J; Groot VP; Rozich NS; Javed AA; Zheng L; Cameron JL; Burkhart RA; Weiss MJ; Wolfgang CL; He J
    Ann Surg; 2021 Jul; 274(1):162-169. PubMed ID: 32304375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary strategies to improve the outcome in locally advanced pancreatic cancer.
    Schneider R; Späth C; Nitsche U; Erkan M; Kleeff J
    Minerva Chir; 2017 Oct; 72(5):424-431. PubMed ID: 28565894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
    Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.